Summary of Key Points Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. is set to list its ordinary shares on the Shenzhen Stock Exchange's ChiNext board on September 25, 2025, following approval from the Shenzhen Stock Exchange [1]. Company Overview - Stock Name: Jianda Zhixin - Stock Code: 301584 - Total Shares Post-IPO: 421,288,509 shares - Number of New Shares Issued: 63,193,277 shares, with no existing shares being transferred [5]. Industry Context - The company belongs to the "F51 Wholesale Industry" as per the classification by the China Association of Listed Companies [3]. - As of September 10, 2025, the average static P/E ratio for the "F51 Wholesale Industry" was 25.73 times [3]. Financial Metrics - The IPO price is set at 7.05 RMB per share, which corresponds to a diluted P/E ratio of 13.29 times based on the lower of the 2024 net profit attributable to the parent company, excluding non-recurring gains and losses [3]. - This P/E ratio is lower than the industry average of 25.73 times but higher than the average P/E ratio of comparable listed companies, which is 11.27 times, indicating a premium of approximately 17.92% [3]. Market Risks - The ChiNext board is characterized by higher investment risks, including unstable performance, operational risks, and a greater likelihood of delisting [3]. - Investors are advised to be aware of the potential for stock price declines and to assess the reasonableness of the IPO pricing carefully [3].
上海建发致新医疗科技集团股份有限公司 首次公开发行股票并在创业板上市之 上市公告书提示性公告